Our research has shown that Cfs derived from cancer patients are biologically more potent than those derived from healthy volunteers. We have observed that treatment of NIH3T3 cells with Cfs isolated from sera of cancer patients trigger a genome-wide deregulation of transcription, chromosomal instability, inflammation and up-regulation of multiple cancer-related pathways encompassing 200 genes. In 30% of our experiments, oncogenic transformation was observed in the treated cells within 72hr - 96hr.